Certolizumab
Certolizumab is a Fab fragment of a humanized monoclonal antibody against tumor necrosis factor-alpha (TNF-α). Differing from the other TNF-α inhibitors due to the absence of Fc fragment and pegylation, it binds to both the soluble and transmembrane forms of TNF-α, creating a strong TNF-α blockage....
Saved in:
Main Author: | Savaş Yaylı (Author) |
---|---|
Format: | Book |
Published: |
Galenos Publishing House,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
by: Lindsey J. Wanberg, et al.
Published: (2024) -
Topical therapies
by: Savaş Yaylı
Published: (2022) -
Certolizumab on treating hidradenitis suppurativa: a brief report
by: Asem Shadid, et al.
Published: (2022) -
Quantitation of certolizumab pegol by validated liquid chromatography methods
by: Clóvis Dervil Appratto Cardoso Júnior, et al.
Published: (2023) -
Profile of certolizumab and its potential in the treatment of psoriatic arthritis
by: Chimenti MS, et al.
Published: (2013)